CVE-2022-48224

Name: CVE-2022-48224
Creator: NVD / NIST
Published: 2023-04-04T16:15:07.23+00:00
License: https://creativecommons.org/publicdomain/zero/1.0/

HIGHCVSS 7.3/10EPSS 0.22%

Last modified Jun 17, 2026

CVE-2022-48224 is a high-severity vulnerability rated 7.3/10 on the CVSS scale. An issue was discovered in Acuant AcuFill SDK before 10.22.02.03. It is installed with insecure permissions (full write access within Program Files). EPSS estimates a 0.22% chance of exploitation in the next 30 days.

Description

An issue was discovered in Acuant AcuFill SDK before 10.22.02.03. It is installed with insecure permissions (full write access within Program Files). Standard users can replace files within this directory that get executed with elevated privileges, leading to a complete arbitrary code execution (elevation of privileges).

Metrics

CVSS 3.1

7.3/10

CVSS:3.1/AV:L/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:H

EPSS Probability

0.22%

12.0th percentile

Probability of exploitation in the next 30 days. Learn more

Weakness Enumeration

CWE-427

Affected Software

Vendor	Product	Versions
Gbgplc	Acuant Acufill Sdk	< 10.22.02.03

References

https://acuant.comNot Applicable
https://hackandpwn.com/disclosures/CVE-2022-48224.pdfThird Party Advisory
https://acuant.comNot Applicable
https://hackandpwn.com/disclosures/CVE-2022-48224.pdfThird Party Advisory

Timeline

Published: Apr 4, 2023
Last Modified: Jun 17, 2026
Status: Modified

Frequently Asked Questions

What is CVE-2022-48224?

How severe is CVE-2022-48224?

CVE-2022-48224 has a CVSS score of 7.3/10 (HIGH severity). The EPSS model estimates a 0.22% probability of exploitation in the next 30 days.

How do I fix CVE-2022-48224?

Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.

Are you affected by CVE-2022-48224?

Run a free Strix scan to check your systems for this vulnerability.

Scan your code now

Source: NVD / NIST